Physical Therapy Marketing Compliance: Direct Access, Outcome Claims, and the State Licensing Board Rules PT Practices Keep Missing
PT practices face a specific compliance pattern around direct access marketing, outcome claims, and supervision language for PTAs. Here's what state PT boards and the FTC focus on.
Physical therapy practices operate under state PT licensing board rules, FTC substantiation rules, and specific considerations around direct access marketing, supervision of PT assistants, and outcome claims. Direct access rules vary state-by-state and affect how PT services can be marketed to consumers. This post covers the compliance framework for PT practices.
Direct access marketing
Direct access laws allow patients to seek PT services without a physician referral. Rules vary by state, with some states having full direct access, others having limited direct access (time limits, visit limits, specific restrictions), and a few having no direct access.
Marketing considerations:
- Accurately represent direct access status in your state.
- If limited direct access applies, disclose the limits (visit limits, time limits, specific conditions requiring physician referral).
- Cross-state marketing (telehealth PT, multi-state practices) must reflect state-specific direct access rules.
Outcome claim patterns
Pattern 1: Specific recovery timeline claims
“Back in action in 6 weeks guaranteed.” Recovery timelines vary enormously by condition, severity, and patient factors. Specific timeline guarantees create substantiation and private-action exposure.
Pattern 2: Surgery-avoidance claims
“Avoid surgery with our PT program.” For appropriate candidates PT may be a non-surgical option; for others surgery may be indicated. Broad surgery- avoidance marketing has drawn state board attention.
Pattern 3: Percentage-success marketing
“95% of our patients return to full function.” Specific percentage claims need substantiation from your actual outcome data or properly-cited literature, not estimates.
Pattern 4: Specialty-specific pain-free claims
“Pain-free pediatric PT,” “pain-free senior rehab.” Absolute-comfort claims conflict with typical PT experience and are enforcement targets.
PT assistant (PTA) supervision
Marketing that implies PTA independence when state rules require supervision is a state PT board concern. Compliant marketing either accurately represents supervision relationships or focuses on PT-performed services.
Dry needling and scope-of-practice
Dry needling has specific state-by-state rules on who can perform it (PTs, acupuncturists, chiropractors vary by state). Marketing dry needling should match actual scope-of-practice authority in your state.
Telehealth PT
Telehealth PT has grown significantly. Marketing considerations:
- State licensure for the PT in the patient’s state.
- Accurate representation of what telehealth PT can and cannot address.
- Specific state rules on telehealth PT (some states more restrictive).
Insurance and cash-pay marketing
PT services vary in insurance coverage. Marketing should accurately represent insurance coverage, cash-pay pricing, and financing options. “We take insurance” marketing should specify what insurance and what co-pays/deductibles typically apply.
Compliant PT marketing framework
- Accurate direct-access representation.State-specific framing.
- Condition-focused practice framing.Describe the kinds of concerns the practice addresses without timeline guarantees.
- Evaluation-forward consultation flow.Initial evaluation as the entry point for determining appropriate care.
- Specific provider credentialing. DPT, specific specializations (OCS, SCS, NCS), specific certifications with accurate sourcing.
- Conservative outcome framing.“Most patients experience meaningful improvement” with appropriate individual-variation language.
Frequently asked questions
Can I market surgery alternatives?
With appropriate clinical context. “PT as a first-line approach before considering surgical options for appropriate candidates” is defensible. Broad surgery-avoidance marketing is more exposure-heavy.
How should I handle patient testimonials?
Standard HIPAA authorization plus FTC typical-experience framing. PT testimonials often feature specific condition recovery; frame these with individual-variation language.
Are there specific state PT board advertising rules?
Yes, varying by state. Some states have specific rules on PT advertising including disclosure requirements and prohibited claim language. Check state-specific rules.
What about performance-focused PT marketing?
Performance PT combines standard PT rules with performance- claim substantiation. Specific performance-outcome claims need substantiation matching the specific claim.
How do I handle pediatric PT marketing?
Apply pediatric marketing considerations (see pediatric practice marketing compliance post) plus standard PT rules. Outcome claims for pediatric developmental intervention need particularly careful substantiation.
What documentation should PT practices maintain?
Standard healthcare marketing documentation plus: direct-access compliance documentation, PTA supervision records, outcome tracking if using practice data for marketing claims, scope-of-practice documentation for specific interventions.
Built for this exact problem
Scan your clinic's content before regulators do.
RegenCompliance checks every word of your marketing against live FDA and FTC enforcement data - and rewrites violations automatically. A 30-second scan can save a $50,000–$5M regulatory response.
Related in the platform
Weekly compliance brief
One email a week. New enforcement actions, rule changes, and tactical fixes. No spam, unsubscribe anytime.
Keep reading
Compounded GLP-1 Marketing Compliance in 2026: What Changed When the Shortage List Closed
When the FDA declared the semaglutide and tirzepatide shortages resolved, the legal basis for routine 503A compounding narrowed. Your existing compounded-GLP-1 marketing was probably written for the old posture. Here is the 2026 rewrite.
Read articleKetamine Clinic Marketing Compliance Guide: IV Ketamine for Depression Without Triggering an FDA Letter
Most ketamine clinic marketing problems are not exotic - they are six or seven repeated phrases that the FDA October 2023 communication and 2024 enforcement actions have already singled out. This guide focuses on the IV ketamine for depression use case and rewrites the patterns that get clinics in trouble.
Read articleNAD+ IV Therapy Marketing and the FDA Position: What Actually Has Approval, What Does Not, and How to Word It
Most NAD+ IV therapy marketing trouble is upstream of the FTC longevity-claim issue. It is the quiet implication that NAD+ has some kind of FDA status it does not have. Here is the actual FDA position and how to word a NAD+ program page around it.
Read article